Boston、MAにおける胃癌の臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、胃癌に関する32件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
被験者募集中
- Dana-Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
被験者募集中第1相
- Massachusetts General Hospital, Boston
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
被験者募集中第3相
- Dana Farber Cancer Institute, Boston
IKS014 in Advanced Solid Tumors That Express HER2
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- Tufts Medical Center, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
被験者募集中第3相
- Massachusetts General Hospital, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
被験者募集中
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
被験者募集中第3相
- Research Site, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
被験者募集中第2相
- Massachusetts General Hospital, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
被験者募集中第1相
- Mass General Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital Cancer Center, Boston
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
被験者募集中第3相
- Tufts Medical Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital - Dana Farber, Boston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- 他2件
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
被験者募集中観察研究
- Dana-Farber Cancer Institute, Boston
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
被験者募集中第2相
- I-Mab Site 1002, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Mass General Hospital, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
被験者募集中
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Comprehensive Outcomes for After Cancer Health
被験者募集中健康なボランティア歓迎
- Dana Farber Cancer Institute, Boston
他の都市における胃癌の試験
- Houston, TX42件の研究
- New York City, NY31件の研究
- Nashville, TN28件の研究
- Baldwin Park, CA22件の研究
- Los Angeles, CA22件の研究
- Arlington, VA20件の研究
- Dallas, TX19件の研究
- San Antonio, TX19件の研究
- St. Louis, MO18件の研究
- Grand Rapids, MI18件の研究
- Washington, DC16件の研究
- Chicago, IL16件の研究
Bostonにおける他の研究
- 乳がん112件の研究
- 非小細胞肺癌90件の研究
- がん（全種類）85件の研究
- 転移性癌63件の研究
- 大腸癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。